PMO Interview with the Innovator Series: Volume 7
Video Categories: PMO Interview with the Innovator Series
Listen as some of the top academic and community thought leaders in multiple myeloma define what precision medicine means to them.
Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer IndexSM (BCI) in treatment decision making.
As we learn more about a person’s genetic makeup, the more we are able to target medicines to his/her needs and benefit. With continued research, Dr. Stainthorpe explains, we will be able to identify markers that allow us to target medicines more precisely to get better performance and reduce waste.